Dr. Daniel James Delitto, MD

Dr. Delitto practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Delitto's NPI, 1396037941, was assigned on May 13, 2011. Dr. Delitto graduated from University of Pittsburgh School of Medicine in 2011. Dr. Delitto holds California license A173758.

Dr. Delitto's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Delitto's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Delitto is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Delitto to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account. Dr. Delitto's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Delitto practices, 5 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Delitto's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Delitto is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Delitto's licenses on file in 3 states: California, Florida and Maryland.

Dmand AI lists abdominal adhesion surgery, colon removal and esophagus, stomach, or upper small intestine surgery among the conditions Dr. Delitto treats.

CMS data shows 141 Medicare services from Dr. Delitto across 5 procedure codes in 2024, for 145 Medicare patients. Medicare paid $16,471 for them.

CMS counts 145 Medicare patients who saw Dr. Delitto in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Delitto's median patient age at 65, with 52% women.

In 2024, Dr. Delitto wrote 52 Medicare Part D claims for 21 patients. 92% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $121 in total drug cost. In 2018, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Delitto for performance year 2024, reported as part of a group. Dr. Delitto accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Delitto as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 46 papers to Dr. Delitto, published from 2015 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Pancreatic Neoplasms, Tumor Microenvironment and Adenocarcinoma. Dr. Delitto has published most often in Cancers (Basel). Dr. Delitto's most frequent co-authors are Steven John Hughes, MD, Kevin Eugene Behrns, MD and Ryan Michael Thomas, MD.

CMS Open Payments shows 10 general payments to Dr. Delitto from 4 drug and device companies from 2018 to 2025. Grants make up the largest share, 91% of the total. Genentech, Inc. paid the most, $18,182.

Dr. Delitto graduated from University of Pittsburgh School of Medicine in 2011.

Dr. Delitto is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.